SCHEMBL6319920

SCHEMBL6319920

Cc1[nH]c(/C=C2\C(=O)Nc3cccc(-c4cccc(CCN(C)C)c4)c32)c(C)c1C(=O)N1CCC(O)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKAA2 P54646 9/20 0.47
PRKAA1 Q13131 9/20 0.47
KDR P35968 12/20 0.45
FLT1 P17948 2/20 0.45
FGFR1 P11362 7/20 0.44
MET P08581 4/20 0.44
MEN1 O00255 2/20 0.44
CDK2 P24941 2/20 0.44
KMT2A Q03164 2/20 0.44
PTK2B Q14289 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
CCNE1 P24864 1/20 0.44
RECQL P46063 1/20 0.44
PDGFRB P09619 7/20 0.42
EGFR P00533 2/20 0.42
PDGFRA P16234 2/20 0.42
RET P07949 3/20 0.41
FLT3 P36888 3/20 0.41
ABL1 P00519 2/20 0.41
ALK Q9UM73 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322333 0.86 KDR (0.56) PRKAA2PRKAA1KDRFLT1FGFR1
SCHEMBL6322137 0.85 KDR (0.43) PRKAA2PRKAA1KDRFLT1FGFR1
SCHEMBL6322409 0.83 KDR (0.42) PRKAA2PRKAA1KDRFLT1FGFR1
SCHEMBL6322488 0.82 KDR (0.49) PRKAA2PRKAA1KDRFLT1FGFR1
SCHEMBL6320490 0.82 KDR (0.53) PRKAA2PRKAA1KDRFLT1FGFR1
SCHEMBL6321855 0.82 KDR (0.53) PRKAA2PRKAA1KDRFLT1FGFR1
SCHEMBL6323471 0.80 KDR (0.39) PRKAA2PRKAA1KDRFLT1FGFR1
SCHEMBL6322315 0.80 KDR (0.42) PRKAA2PRKAA1KDRFLT1FGFR1
SCHEMBL6324286 0.79 KDR (0.46) PRKAA2PRKAA1KDRFLT1FGFR1
SCHEMBL6321957 0.79 KDR (0.44) PRKAA2PRKAA1KDRFLT1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 PRKAA2 196/4885PRKAA1 192/4885KDR 819/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 PRKAA2 196/4885PRKAA1 192/4885KDR 819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.